# Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer

> **NCT00537095** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 164 (actual)

## Conditions studied

- Thyroid Neoplasms

## Interventions

- **DRUG:** Vandetanib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00537095
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09-28
- **Primary completion:** 2009-12-02
- **Final completion:** 2021-11-24
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00537095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00537095, "Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00537095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*